|Mr. Ilan Danieli||Founder, Pres, CEO & Director||263.56k||N/A||1972|
|Mr. Carl R. Iberger||CFO & Sec.||210.67k||N/A||1953|
|Mr. Ahmed Zaki Sabet||Chief Operating Officer||173.76k||N/A||1987|
|Mr. Stephen R. Miller||Chief Commercial Officer||252.21k||N/A||1966|
|Ms. Miri Chiko-Radomski||Gen. Counsel||N/A||N/A||N/A|
|Mr. Douglas Sites||VP of Sales||N/A||N/A||N/A|
|Mr. Ayman Mohamed M.D.||Sr. VP of R&D and Laboratory Operations||N/A||N/A||1986|
|Mr. Ori Karev||Chief Strategy Officer||N/A||N/A||N/A|
Precipio, Inc., a cancer diagnostics company, provides diagnostic products and services in the United States oncology market. Its product consists of clinical diagnostic services. The company's clinical diagnostic services focus on the diagnosis of different hematopoietic or blood-related cancers to oncologists. Its cytogenetics media IV-Cell enables laboratories to arrive at more accurate results; and HemeScreen panel enables hospitals and laboratories to run an important genetic mutation test. It serves oncologists, hospitals, reference laboratories, and pharma and biotech companies. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment, such as the Yale School of Medicine and Harvard's Dana-Farber Cancer Institute. The company is based in New Haven, Connecticut.
Precipio, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.